老年患者舌下右美托咪定给药后严重低血压一例
本文报告一例88岁高血压、血管性痴呆及非ST段抬高型心肌梗死患者,因躁动接受120 µg舌下右美托咪定后1小时内血压从102/49降至62/40 mm Hg,血红蛋白从12.1降至6.9 g/dL,影像发现可能与治疗性抗凝及双联抗血小板治疗相关的肌内血肿。Naranjo评分为4分提示可能的不良反应。作者强调老年及心血管储备有限患者使用右美托咪定时需谨慎选例、优化剂量并密切监测。
要点
- 老年多病共存患者舌下右美托咪定可致严重低血压。
- 用药后需密切监测血压及血红蛋白变化。
- 抗凝及双联抗血小板治疗可能增加出血风险。
核心结论
- 舌下右美托咪定在老年、多病共存及近期抗凝患者中可能引起具有临床意义的低血压。
研究设计与样本
- 单例病例报告,患者为88岁女性,因躁动接受120 µg舌下右美托咪定。
主要发现
- 给药后1小时内血压从102/49降至62/40 mm Hg。
- 同期血红蛋白从12.1降至6.9 g/dL,需输血并排查活动性出血。
- 影像发现大型肌内血肿,可能与治疗性抗凝及双联抗血小板治疗下的肌内注射相关。
- Naranjo评分为4分,提示可能为右美托咪定不良反应,但舌下给药与低血压的强时间关联支持其贡献作用。
关键数值与推荐
- Naranjo评分为4分,对应可能的不良药物反应。
临床怎么用
- 老年及心血管储备有限患者使用右美托咪定时应仔细选择患者、优化剂量并密切监测。
- 对近期抗凝或双联抗血小板治疗患者,需关注出血风险及血红蛋白变化。
局限性
- 为单例病例报告,无法确立因果关系或推广至其他人群。
- Naranjo评分仅提示可能的不良反应,不能排除其他混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sublingual dexmedetomidine is a recently introduced α2-adrenergic agonist approved for management of agitation in patients with schizophrenia or bipolar disorder. Published safety data on the use of this drug outside of clinical trials is limited. SUMMARY: We describe an 88-year-old patient with hypertension, vascular dementia, and non-ST segment elevation myocardial infarction who experienced profound hypotension after receiving sublingual dexmedetomidine for agitation. The patient was boarding in the emergency department due to hospital overcrowding and developed delirium with severe agitation. After QT interval prolongation limited further antipsychotic use, a 120-µg dose of sublingual dexmedetomidine was administered. Within 1 hour, the patient's blood pressure fell from 102/49 to 62/40 mm Hg. Concomitantly, her hemoglobin declined from 12.1 to 6.9 g/dL, prompting a blood transfusion and investigation of active bleeding. Imaging revealed a large intramuscular hematoma possibly related to intramuscular injections in the setting of therapeutic anticoagulation and dual antiplatelet therapy. The Naranjo score was 4, indicating a possible adverse drug reaction to dexmedetomidine; however, the strong temporal association with sublingual administration supports a contributory role. CONCLUSION: This case highlights the hemodynamic vulnerability of older adults, especially those with comorbidities and recent anticoagulation. While sublingual dexmedetomidine offers a noninvasive option for agitation management, its hypotensive potential may be clinically significant in this population. Our findings underscore the need for careful patient selection, dose optimization, and close monitoring when using dexmedetomidine in elderly patients, especially those with limited cardiovascular reserve. Further research is needed to guide safe dosing in geriatric and medically complex populations.
引用
- Coralic Z, Allai M, Hwang C, et al. Severe hypotension following sublingual dexmedetomidine administration in an elderly patient. Am J Health Syst Pharm. 2026. PMID: 41351540. doi:10.1093/ajhp/zxaf335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。